FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,726 | -92.8% | 34,305 | -83.8% | 0.00% | – |
| Q2 2023 | $1,009,710 | -34.1% | 212,124 | -21.1% | 0.00% | – |
| Q1 2023 | $1,532,883 | +199.7% | 268,927 | +430.5% | 0.00% | – |
| Q4 2022 | $511,472 | -51.1% | 50,691 | +8.7% | 0.00% | – |
| Q3 2022 | $1,045,000 | -7.6% | 46,620 | +2.2% | 0.00% | – |
| Q2 2022 | $1,131,000 | -79.5% | 45,609 | -68.0% | 0.00% | -100.0% |
| Q1 2022 | $5,520,000 | -48.2% | 142,398 | -21.8% | 0.00% | -66.7% |
| Q4 2021 | $10,658,000 | -52.8% | 182,145 | -52.2% | 0.00% | -40.0% |
| Q3 2021 | $22,587,000 | -20.4% | 381,091 | +16.6% | 0.01% | -16.7% |
| Q2 2021 | $28,360,000 | +65.4% | 326,769 | +57.1% | 0.01% | +50.0% |
| Q1 2021 | $17,149,000 | -17.2% | 208,008 | -8.7% | 0.00% | -20.0% |
| Q4 2020 | $20,707,000 | +107.3% | 227,731 | -14.1% | 0.01% | +66.7% |
| Q3 2020 | $9,988,000 | -15.3% | 265,046 | -22.9% | 0.00% | 0.0% |
| Q2 2020 | $11,796,000 | +25.4% | 343,800 | -18.8% | 0.00% | 0.0% |
| Q1 2020 | $9,409,000 | -3.6% | 423,651 | -15.1% | 0.00% | 0.0% |
| Q4 2019 | $9,765,000 | +38.8% | 498,960 | +10.1% | 0.00% | +50.0% |
| Q3 2019 | $7,037,000 | -27.6% | 453,115 | -5.4% | 0.00% | -33.3% |
| Q2 2019 | $9,725,000 | +292.9% | 479,015 | +240.0% | 0.00% | +200.0% |
| Q1 2019 | $2,475,000 | +18.7% | 140,885 | -13.3% | 0.00% | 0.0% |
| Q4 2018 | $2,085,000 | -32.5% | 162,552 | -14.2% | 0.00% | 0.0% |
| Q3 2018 | $3,088,000 | +131.3% | 189,563 | +61.2% | 0.00% | – |
| Q2 2018 | $1,335,000 | +30.6% | 117,623 | +12.4% | 0.00% | – |
| Q1 2018 | $1,022,000 | -49.0% | 104,647 | -68.1% | 0.00% | -100.0% |
| Q4 2017 | $2,004,000 | +107.7% | 328,023 | +34.6% | 0.00% | – |
| Q3 2017 | $965,000 | +17.7% | 243,754 | -3.7% | 0.00% | – |
| Q2 2017 | $820,000 | -35.9% | 253,063 | -10.0% | 0.00% | – |
| Q1 2017 | $1,279,000 | +1753.6% | 281,111 | +926.7% | 0.00% | – |
| Q4 2016 | $69,000 | -16.9% | 27,379 | +2.7% | 0.00% | – |
| Q3 2016 | $83,000 | +4050.0% | 26,667 | +2566.7% | 0.00% | – |
| Q2 2016 | $2,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2016 | $2,000 | -33.3% | 1,000 | 0.0% | 0.00% | – |
| Q4 2015 | $3,000 | -40.0% | 1,000 | 0.0% | 0.00% | – |
| Q3 2015 | $5,000 | -61.5% | 1,000 | -50.0% | 0.00% | – |
| Q2 2015 | $13,000 | -35.0% | 2,000 | -50.0% | 0.00% | – |
| Q1 2015 | $20,000 | +100.0% | 4,000 | +100.0% | 0.00% | – |
| Q4 2014 | $10,000 | -89.7% | 2,000 | -79.9% | 0.00% | – |
| Q1 2014 | $97,000 | – | 9,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |